These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

128 related articles for article (PubMed ID: 23566532)

  • 1. Overexpression of factor VII ameliorates bleeding diathesis of factor VIII-deficient mice with inhibitors.
    Yasumoto A; Madoiwa S; Kashiwakura Y; Ishiwata A; Ohmori T; Mizukami H; Ozawa K; Sakata Y; Mimuro J
    Thromb Res; 2013 May; 131(5):444-9. PubMed ID: 23566532
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Gene Delivery of Activated Factor VII Using Alternative Adeno-Associated Virus Serotype Improves Hemostasis in Hemophiliac Mice with FVIII Inhibitors and Adeno-Associated Virus Neutralizing Antibodies.
    Sun J; Hua B; Chen X; Samulski RJ; Li C
    Hum Gene Ther; 2017 Aug; 28(8):654-666. PubMed ID: 28478688
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Novel therapeutic approach for hemophilia using gene delivery of an engineered secreted activated Factor VII.
    Margaritis P; Arruda VR; Aljamali M; Camire RM; Schlachterman A; High KA
    J Clin Invest; 2004 Apr; 113(7):1025-31. PubMed ID: 15057309
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Phenotypic correction of hemophilia A by ectopic expression of activated factor VII in platelets.
    Ohmori T; Ishiwata A; Kashiwakura Y; Madoiwa S; Mitomo K; Suzuki H; Hasegawa M; Mimuro J; Sakata Y
    Mol Ther; 2008 Aug; 16(8):1359-65. PubMed ID: 18523449
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Liver-restricted expression of the canine factor VIII gene facilitates prevention of inhibitor formation in factor VIII-deficient mice.
    Ishiwata A; Mimuro J; Mizukami H; Kashiwakura Y; Takano K; Ohmori T; Madoiwa S; Ozawa K; Sakata Y
    J Gene Med; 2009 Nov; 11(11):1020-9. PubMed ID: 19757487
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Plasma elimination kinetics for factor VII are independent of its activation to factor VIIa and complex formation with plasma inhibitors.
    Petersen LC; Elm T; Ezban M; Krogh TN; Karpf DM; Steinø A; Olsen EH; Sørensen BB
    Thromb Haemost; 2009 May; 101(5):818-26. PubMed ID: 19404533
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Successful treatment of canine hemophilia by continuous expression of canine FVIIa.
    Margaritis P; Roy E; Aljamali MN; Downey HD; Giger U; Zhou S; Merricks E; Dillow A; Ezban M; Nichols TC; High KA
    Blood; 2009 Apr; 113(16):3682-9. PubMed ID: 19109232
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Gene-based continuous expression of FVIIa for the treatment of hemophilia.
    Margaritis P
    Front Biosci (Schol Ed); 2012 Jan; 4(1):287-99. PubMed ID: 22202061
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Heterogeneity of the immune response to adenovirus-mediated factor VIII gene therapy in different inbred hemophilic mouse strains.
    Rawle FE; Shi CX; Brown B; McKinven A; Tinlin S; Graham FL; Hough C; Lillicrap D
    J Gene Med; 2004 Dec; 6(12):1358-68. PubMed ID: 15493040
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Heterozygous antithrombin deficiency improves in vivo haemostasis in factor VIII-deficient mice.
    Bolliger D; Szlam F; Suzuki N; Matsushita T; Tanaka KA
    Thromb Haemost; 2010 Jun; 103(6):1233-8. PubMed ID: 20352163
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Phenotype correction of hemophilia A mice with adeno-associated virus vectors carrying the B domain-deleted canine factor VIII gene.
    Ishiwata A; Mimuro J; Kashiwakura Y; Niimura M; Takano K; Ohmori T; Madoiwa S; Mizukami H; Okada T; Naka H; Yoshioka A; Ozawa K; Sakata Y
    Thromb Res; 2006; 118(5):627-35. PubMed ID: 16371232
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Levels of prothrombin activation peptide F1+2 in patients with a bleeding tendency.
    Ingerslev J; Holm M; Christiansen K; Knudsen L; Négrier C
    Blood Coagul Fibrinolysis; 1998 Mar; 9 Suppl 1():S129-34. PubMed ID: 9819044
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Catalytic domain modification and viral gene delivery of activated factor VII confers hemostasis at reduced expression levels and vector doses in vivo.
    Margaritis P; Roy E; Faella A; Downey HD; Ivanciu L; Pavani G; Zhou S; Bunte RM; High KA
    Blood; 2011 Apr; 117(15):3974-82. PubMed ID: 21325603
    [TBL] [Abstract][Full Text] [Related]  

  • 14. AAV mediated genome engineering with a bypass coagulation factor alleviates the bleeding phenotype in a murine model of hemophilia B.
    Sarangi P; Kumar N; Sambasivan R; Ramalingam S; Amit S; Chandra D; Jayandharan GR
    Thromb Res; 2024 Jun; 238():151-160. PubMed ID: 38718473
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Safety, pharmacokinetics and efficacy of factor VIIa formulated with PEGylated liposomes in haemophilia A patients with inhibitors to factor VIII--an open label, exploratory, cross-over, phase I/II study.
    Spira J; Plyushch O; Zozulya N; Yatuv R; Dayan I; Bleicher A; Robinson M; Baru M
    Haemophilia; 2010 Nov; 16(6):910-8. PubMed ID: 20491957
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Long-term efficacy of adeno-associated virus serotypes 8 and 9 in hemophilia a dogs and mice.
    Sarkar R; Mucci M; Addya S; Tetreault R; Bellinger DA; Nichols TC; Kazazian HH
    Hum Gene Ther; 2006 Apr; 17(4):427-39. PubMed ID: 16610930
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Advances in gene therapy using factor VIIa in hemophilia.
    Margaritis P; High KA
    Semin Hematol; 2006 Jan; 43(1 Suppl 1):S101-4. PubMed ID: 16427374
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Relationship between factor VII activity and clinical efficacy of recombinant factor VIIa given by continuous infusion to patients with factor VIII inhibitors.
    Santagostino E; Morfini M; Rocino A; Baudo F; Scaraggi FA; Gringeri A
    Thromb Haemost; 2001 Oct; 86(4):954-8. PubMed ID: 11686352
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Partial correction of murine hemophilia A with neo-antigenic murine factor VIII.
    Sarkar R; Gao GP; Chirmule N; Tazelaar J; Kazazian HH
    Hum Gene Ther; 2000 Apr; 11(6):881-94. PubMed ID: 10779165
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Establishment of a cell line expressing recombinant factor VII and its subsequent conversion to active form FVIIa through hepsin by genetic engineering method.
    Halabian R; Roudkenar MH; Esmaeili NS; Masroori N; Roushandeh AM; Najafabadi AJ
    Vox Sang; 2009 May; 96(4):309-15. PubMed ID: 19175565
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.